Reducing dangerous lung inflammation after respiratory infections
Treatment of Inflammatory Complications of Respiratory Infection
['FUNDING_OTHER'] · RESPANA THERAPEUTICS, INC. · NIH-11144440
This project is developing a new antibody medicine to calm harmful lung inflammation in adults with severe respiratory infections.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESPANA THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11144440 on ClinicalTrials.gov |
What this research studies
The team is developing a monoclonal antibody called RT-002 that targets a receptor (SP-R210) involved in lung inflammation. In mice the antibody lowered death rates and helped restore healthier lungs. Researchers are testing how RT-002 acts on human blood cells in lab assays to confirm it engages the intended immune target. The goal is to prepare the antibody for human clinical trials so it could be offered to patients in the future.
Who could benefit from this research
Good fit: Adults with severe or worsening respiratory infections who are at risk of inflammatory lung complications would be the most likely candidates for future trials.
Not a fit: Children, people with only mild infections, or conditions not driven by the targeted inflammatory pathway may not benefit from this approach.
Why it matters
Potential benefit: If successful, this therapy could reduce life-threatening lung inflammation and lung damage across different respiratory infections.
How similar studies have performed: Other treatments that target host-driven inflammation have had mixed results, and targeting SP-R210 is a novel approach with promising animal data but limited human evidence so far.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESPANA THERAPEUTICS, INC. — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LARK, MICHAEL WILLIAM — RESPANA THERAPEUTICS, INC.
- Study coordinator: LARK, MICHAEL WILLIAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections